hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06338813 id: Merve Unutmaz briefTitle: Digital Manometry for Intra-Abdominal Pressure Measurement in Ileus overallStatus: COMPLETED date: 2022-10-30 date: 2023-02-22 date: 2023-03-01 date: 2024-04-01 date: 2024-04-01 name: Ankara City Hospital Bilkent class: OTHER briefSummary: Although many measurement techniques have been tried for intra-abdominal pressure, the Kron technique is currently the gold standard method. However, the search for other methods continues due to its long application time, the need for more equipment, and impracticality. Consequently, the investigators sought to investigate a quicker and more accessible method suitable for successful intra-abdominal pressure measurement in the emergency department. This study aimed to compare intra-abdominal pressure measurements in patients diagnosed with ileus using a digital manometer and the Kron Technique. conditions: Ileus studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: CROSSOVER primaryPurpose: SCREENING masking: TRIPLE whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 30 type: ACTUAL name: Digital Manometry measure: Digital manometer measuring for Intraabdominal Pressure sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ankara City Hospital city: Ankara zip: 06100 country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06338800 id: PSY-2324-S-0134 briefTitle: One Session Virtual Reality During Ongoing Treatment for Anxiety: Feasibility in Children and Adolescents overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-04 date: 2025-12 date: 2024-04-01 date: 2024-04-01 name: Accare class: OTHER briefSummary: The goal of this study is to evaluate one session with exposure with Virtual Reality (VR) in in children and adolescents, aged 8-18 years with an anxiety disorder. The main questions it aims to answer are:
3. What are possible working mechanisms of VR exposure? During ongoing treatment, participants will receive a session of exposure with VR. conditions: Anxiety Disorders conditions: Exposure conditions: Social Anxiety Disorder studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: During ongoing treatment for their anxiety disorder 30 children and adolescents (8-18 years) with an anxiety disorder will receive a session of exposure with VR. Before the session expectations of VR exposure will be assessed. Before and after the session willingness to participate in exposure in vivo will be measured. During the session anxiety, idiosyncratic expectations, and self-efficacy are measured. After the session, positive effects, experiences, and negative side effects will be asked for. primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: One session exposure with Virtual Reality measure: Willingness to participate in exposure in vivo measure: Idiosyncratic expectations measure: Anxiety measure: Expectations of Virtual Reality measure: Acceptability sex: ALL minimumAge: 8 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06338787 id: 23-0826.2 briefTitle: A Novel Iron-Based Supplement for Athletes Aged 14-17 overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-09 date: 2024-12 date: 2024-04-01 date: 2024-04-01 name: University of Calgary class: OTHER name: Mitacs name: Natural Sciences and Engineering Research Council, Canada briefSummary: Female endurance athletes are susceptible to iron deficiency and this can impact their exercise performance. This study aims to assess the efficacy of a novel iron supplement in improving iron status, gut microbiome, and exercise performance in endurance-trained females. conditions: Iron Deficiencies studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: FeSC measure: Iron Status measure: Hemoglobin measure: Lower Gut microbiome measure: Exercise Capacity measure: Gastrointestinal Symptoms 1 measure: Gastrointestinal Symptoms 2 measure: Sleepiness measure: Stress and Recovery sex: FEMALE minimumAge: 14 Years maximumAge: 17 Years stdAges: CHILD hasResults: False
nctId: NCT06338774 id: 202310129 id: R33AG078041 type: NIH link: https://reporter.nih.gov/quickSearch/R33AG078041 briefTitle: Cognitive Control to Boost Physical Activity Adherence acronym: BOOST overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2027-05-01 date: 2027-11-30 date: 2024-04-01 date: 2024-04-02 name: University of Iowa class: OTHER name: Northeastern University name: National Institute on Aging (NIA) briefSummary: This trial is designed to develop and test the efficacy of cognitive training strategies to improve self-regulatory capacities for middle-aged adults to adopt and sustain a physically active lifestyle. The main questions it aims to answer are:
* Visit the laboratory before and after cognitive training, and before and after physical training, to complete assessments of cognition and aerobic fitness conditions: Physical Inactivity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Six week parallel group intervention, followed by a 12 week exercise program. primaryPurpose: BASIC_SCIENCE masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 264 type: ESTIMATED name: Cognitive training name: Exercise measure: Physical Activity Adherence sex: ALL minimumAge: 40 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Psychological and Brain Sciences Building city: Iowa City state: Iowa zip: 52242 country: United States name: Michelle W Voss, PhD role: CONTACT phone: 319-335-2057 email: michelle-voss@uiowa.edu name: Ruthina Malone role: CONTACT phone: 319-335-2407 email: ruthina-malone@uiowa.edu name: Michelle Voss, PhD role: PRINCIPAL_INVESTIGATOR lat: 41.66113 lon: -91.53017 facility: Center for Cognitive and Brain Health city: Boston state: Massachusetts zip: 02115 country: United States name: Charles Hillman, PhD role: CONTACT phone: 617-373-8342 email: c.hillman@northeastern.edu name: Virginia Davis role: CONTACT phone: 617-373-3448 email: vi.davis@northeastern.edu name: Charles Hillman, PhD role: PRINCIPAL_INVESTIGATOR name: Arthur F Kramer, PhD role: SUB_INVESTIGATOR lat: 42.35843 lon: -71.05977 hasResults: False
nctId: NCT06338761 id: E-cigarette PCI briefTitle: Switching to E-cigarette After PCI acronym: E-cig-PCI overallStatus: RECRUITING date: 2024-01-01 date: 2024-12-31 date: 2025-12-31 date: 2024-04-01 date: 2024-04-01 name: Samsung Medical Center class: OTHER briefSummary: Despite the increasing popularity of electronic cigarettes (E-cigarettes), the prognostic impact of switching to E-cigarettes in smokers with coronary artery disease (CAD) who underwent percutaneous coronary intervention (PCI) remains uncertain. conditions: Coronary Artery Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 17442 type: ESTIMATED name: Smoking cessation name: Switching to E-cigarette measure: MACE measure: Cardiovascular death measure: All-cause death measure: Spontaneous myocardial infarction measure: Repeat revascularization sex: ALL minimumAge: 20 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Samsung Medical Center status: RECRUITING city: Seoul country: Korea, Republic of name: Ki Hong Choi, MD role: CONTACT phone: 82-2-3410-3419 email: cardiokh@gmail.com lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06338748 id: 24-157 briefTitle: Accuracy of the Dexcom G7 Continuous Glucose Monitoring System Following Cardiac Surgery acronym: DexcomG7 overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-06-01 date: 2025-12-01 date: 2024-04-01 date: 2024-04-01 name: The Cleveland Clinic class: OTHER name: DexCom, Inc. briefSummary: This is a prospective longitudinal study to study the agreement between a continuous glucose monitoring system (CGMS) versus current blood glucose monitoring. Subjects in this study will have their blood glucose measured regularly every 1-3 hours with current methods in the Cardiovascular Intensive Care Unit (CVICU), and by Point of Care (POC) fingerstick glucose using the Accucheck Inform II on the regular floors, and the CGMS reading at the same time will be captured. Subjects will have measurements taken throughout their stay in the CVICU and on the regular floors. Agreement and correlation between systems, as well as errors, will be calculated. conditions: Continuous Glucose Monitoring studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Patients undergoing heart surgery at the Cleveland Clinic (main campus) who would normally be tested for high sugar levels by poking a finger and using a test strip. primaryPurpose: OTHER masking: NONE maskingDescription: The study will involve using blinded Dexcom G7 continuous glucose monitoring (CGM) devices count: 28 type: ESTIMATED name: Continuous glucose monitor (CGM) Dexcom G7 used in blinded mode measure: Compare accuracy of glucose readings obtained from Dexcom G7 compared to blood glucose obtained from arterial blood gas (ABG) or peripheral/central venous catheter or fingerstick point of care (POC) while patients are in the CVICU measure: Compare accuracy of glucose readings obtained from Dexcom G7 compared to blood glucose obtained from fingerstick POC glucose when patients are on the regular floors sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Cleveland Clinic Foundation city: Cleveland state: Ohio zip: 44195 country: United States name: Kimberly Jenkins role: CONTACT phone: 216-445-4791 email: jenkink@ccf.org name: Kimberly Jenkins role: CONTACT phone: (216) 445-4791 email: jenkink@ccf.org lat: 41.4995 lon: -81.69541 hasResults: False
nctId: NCT06338735 id: 14540 briefTitle: Ultra-High Frequency Ultrasonography in Sjögren's Syndrome acronym: UltraSjögren overallStatus: RECRUITING date: 2016-01-11 date: 2026-12-31 date: 2030-12 date: 2024-04-01 date: 2024-04-01 name: University of Pisa class: OTHER briefSummary: Patients diagnosed with a diagnosis of Sjogren's syndrome performed according to the ACR/EULAR criteria will be included in the study. Sjogren's syndrome diagnosis will be performed following a complete diagnostic work-up involving rheumatologic assessment, glandular functional tests, and blood testing for anti-Ro(SSA) antibodies. Conventional ultrasonography of major salivary glands and ultra-high frequency ultrasonography (70 MHz) of minor salivary glands will be performed, and the scans assessed using the Outcome Measures in Rheumatology (OMERACT) scoring system (Score 0 normal glandular tissue, Score 1 mild glandular alteration, fine echogenicity or diffuse hypo-echogenicity, Score 2 moderate glandular alteration and focal hypoechoic areas with partial conservation of normal parenchyma, Score 3 diffuse presence of hypoechoic areas in the absence of normal glandular parenchyma with glandular fibrosis. Focus Score will be assessed following biopsy of minor salivary glands. conditions: Sjogren's Syndrome studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 800 type: ESTIMATED name: Ultra-High Frequency Ultrasound scan of minor salivary glands measure: OMERACT score measure: Correspondence between ultrasonography and histology sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Pisa status: RECRUITING city: Pisa zip: 56126 country: Italy name: Rossana Izzetti role: CONTACT phone: +39050993037 email: rossana.izzetti@unipi.it name: Rossana Izzetti role: PRINCIPAL_INVESTIGATOR lat: 43.70853 lon: 10.4036 hasResults: False
nctId: NCT06338722 id: 23-397 briefTitle: Making it Work Program for Systemic Sclerosis overallStatus: RECRUITING date: 2023-12-08 date: 2024-07-31 date: 2024-09-30 date: 2024-04-01 date: 2024-04-01 name: University of New Mexico class: OTHER briefSummary: The purpose of this clinical trial is to see if an online intervention program for people with Systemic Sclerosis (scleroderma) helps keep people in the workforce and increase self-confidence in dealing with challenges at work. The program is called Making it Work Systemic Sclerosis.
People in the Making it Work group will complete questionnaires and attend one 2 hour meetings each week for 5 weeks and meet with an occupational therapist and vocational counselor. People in the wait list control group will complete the questionnaires and participate in the program at a later point in time. conditions: Scleroderma, Systemic studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Intervention receives the Making it work program Wait list Control receives usual care but will be offered the program after the intervention groups finish primaryPurpose: TREATMENT masking: NONE maskingDescription: People will know what group they are in when they are invited to attend the intervention sessions count: 50 type: ESTIMATED name: Making it Work Systemic Sclerosis measure: Job Related Self-efficacy Scale measure: Job Self-Efficacy Scale measure: Work Productivity and Activity Impairment Questionnaire Specific Health Problem Subscale measure: The Work Instability Scale sex: ALL minimumAge: 18 Years maximumAge: 67 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of New Mexico status: RECRUITING city: Albuquerque state: New Mexico zip: 87131-0001 country: United States name: Janet L Poole, PhD role: CONTACT phone: 505-272-8276 email: jpoole@salud.unm.edu lat: 35.08449 lon: -106.65114 hasResults: False
nctId: NCT06338709 id: 11-002 briefTitle: Clinical Study Protocol for the Assessment of Safety and Efficacy of the BARICLIP® overallStatus: NOT_YET_RECRUITING date: 2024-09 date: 2025-08 date: 2026-08 date: 2024-04-01 date: 2024-04-01 name: Advanced Bariatric Technology class: INDUSTRY name: NAMSA briefSummary: Overweight and obesity are at epidemic proportions in the world population as well as in the United States, where nearly 42% of the adult population(1) is considered to meet the definition of obesity, namely a body mass index ("BMI") ≥ 30 kg/m2. Well-established links between obesity and increased morbidities and mortality make treatment of the utmost importance; however, there continues to be a significant unmet need for more effective treatments for obesity. Bariatric surgery is recognized as an effective treatment for obese patients, particularly in more severe cases where surgical restriction of the stomach's capacity and outlet size are considered necessary. The BariClip® is a laparoscopically implanted device for treatment of obesity and serves as an alternative to current existing technology for use in bariatric surgery. The BariClip® is a medical device, non-adjustable, resembling a clip that is placed parallel to the greater curvature of the stomach, causing restriction of the gastric lumen in a vertical fashion. This multi-center, randomized, moderate-lifestyle (program of diet and exercise) controlled pivotal study of the BariClip® device is intended to gather data to objectively support its safety and effectiveness for the treatment of obesity in adults and to ultimately support marketing authorization of this device as a viable alternative to existing bariatric surgical procedures. Specifically, this study aims to look at efficacy of the BariClip® device with regards to weight loss metrics and secondary health metrics and safety of the BariClip® device with regards to serious adverse events. conditions: Overweight and Obesity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 165 type: ESTIMATED name: BariClip® Device Treatment measure: Achieving ≥ 5% total body weight loss (TBWL) in 50% of treated subjects measure: Achieving ≥ 5% superiority margin for weight loss in the treated group as compared to the control group measure: Weight and Height will be combined to report BMI in kg/m^2 measure: Blood Pressure (BP) in mmHg, both systolic and diastolic measure: Diagnosis and/or Change in Severity of Diabetes Mellitus (DM) measure: Weight in kilograms measure: Height in meters measure: Waist Circumference in centimeters measure: Incidence of Serious Adverse Events (SAEs) sex: ALL minimumAge: 22 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06338696 id: COA-CREC070/2023 briefTitle: Thailand ATTR-CM Registry overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2029-06-01 date: 2030-06-30 date: 2024-04-01 date: 2024-04-01 name: Mahidol University class: OTHER name: Pfizer briefSummary: The investigators of this registry aim to study the natural history, clinical presentation, characteristics, and imaging findings of patients diagnosed with ATTR amyloidosis in Thailand longitudinally. This will enable the investigators to study this disease in depth. With a better understanding, the investigators can aim to develop early screening programs for at-risk patients, raising awareness among non-cardiologists. As amyloid-specific therapies have now become available in Thailand, the findings of this registry can be helpful for epidemiological studies in Thailand. conditions: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 105 type: ESTIMATED name: No intervention measure: Rate of death measure: Rate of heart failure hospitalization measure: Transthyretin (ATTR) amyloidosis medication sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Faculty of Medicine at Chulalongkorn University city: Bangkok country: Thailand name: Sarinya Puwanant, MD role: CONTACT name: Sarinya Puwanant, MD role: PRINCIPAL_INVESTIGATOR lat: 13.75398 lon: 100.50144 facility: Faculty of Medicine Ramathibodi hospital, Mahidol University city: Bangkok country: Thailand name: Teerapat Yingchoncharoen, MD role: CONTACT name: Teerapat Yingchoncharoen, MD role: PRINCIPAL_INVESTIGATOR lat: 13.75398 lon: 100.50144 facility: Faculty of Medicine Siriraj Hospital, Mahidol University city: Bangkok country: Thailand name: Kanchalaporn Jirataiporn, B.N.S role: CONTACT name: Srisakul Chirakarnjanakorn, MD role: PRINCIPAL_INVESTIGATOR name: Adisak Maneesai, MD role: SUB_INVESTIGATOR name: Porntera Sethalao, MD role: SUB_INVESTIGATOR lat: 13.75398 lon: 100.50144 facility: Phramongkutklao Hospital city: Bangkok country: Thailand name: Hutsaya Prasitdumrong, MD role: CONTACT name: Hutsaya Prasitdumrong, MD role: PRINCIPAL_INVESTIGATOR lat: 13.75398 lon: 100.50144 facility: Faculty of Medicine Chiang Mai University city: Chiang Mai country: Thailand lat: 18.79038 lon: 98.98468 facility: Queen Sirikit Heart Center of The Northeast city: Khon Kaen country: Thailand name: Vichai Senthong, MD role: CONTACT name: Vichai Senthong, MD role: PRINCIPAL_INVESTIGATOR lat: 16.44671 lon: 102.833 facility: Faculty of Medicine, Thammasat University city: Pathum Thani country: Thailand name: Adisai Buakhamsri, MD role: CONTACT name: Adisai Buakhamsri, MD role: PRINCIPAL_INVESTIGATOR lat: 14.01346 lon: 100.53049 facility: Prince of Songkla University city: Songkhla country: Thailand lat: 7.19882 lon: 100.5951 hasResults: False
nctId: NCT06338683 id: QRCH-2024001 briefTitle: Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer overallStatus: RECRUITING date: 2024-03-20 date: 2027-03-20 date: 2028-03-20 date: 2024-03-29 date: 2024-03-29 name: Qinghai Red Cross Hospital class: OTHER briefSummary: This study aims to assess the impact of adding olanzapine to nutritional advice and standard anti-tumor therapy on the survival and safety of patients with locally advanced, unresectable or metastatic gastric cancer, esophageal cancer, hepato-pancreaticobiliary cancer, and lung cancer. Researchers seek to determine whether olanzapine can improve progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) in advanced cancer patients who received standard anti-tumor therapy, and investigate the relationship between olanzapine-induced weight changes and patient survival. conditions: Advanced Cancer conditions: Olanzapine conditions: Progression Free Survival studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 230 type: ESTIMATED name: Olanzapine 2.5 MG name: Standard anti-tumor treatment name: Nutritional advice measure: Comparing the difference in Median PFS between the two groups measure: Comparing the difference in Median OS between the two groups measure: Comparing the difference in ORR between the two groups measure: Comparing the difference in the incidence of ≥3% weight loss between the two groups measure: Comparing the difference in BMI between the two groups measure: Comparing the difference in the improvement in other symptoms (appetite, nausea, fatigue, insomnia) between the two groups measure: Comparing the difference in Quality of life in the overall stage between the two groups measure: neutrophil-to-lymphocyte ratio measure: platelet-to-lymphocyte ratio measure: C-reactive protein (CRP) concentration measure: concentration of albumin measure: Level of interleukin (IL)-6 and IL-8 measure: Comparing the difference in the side effects of olanzapine treatment between the two groups sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Qinghai Red Cross Hospital status: RECRUITING city: Xining state: Qinghai zip: 810000 country: China name: Qiuxia Dong, Dr role: CONTACT phone: 0971-8267613 email: 2816278916@qq.com lat: 36.62554 lon: 101.75739 hasResults: False
nctId: NCT06338670 id: CLTD5839 briefTitle: Clinical Performance of the Osia 3 Sound Processor Compared With the Osia 2 Sound Processor in Adult Osia Implant Users acronym: RECONNECT overallStatus: NOT_YET_RECRUITING date: 2024-04-08 date: 2024-11-22 date: 2024-11-22 date: 2024-03-29 date: 2024-03-29 name: Cochlear class: INDUSTRY name: Avania briefSummary: This study aims to investigate the clinical performance of the Osia 3 Sound Processor in comparison to the Osia 2 Sound Processor in adults with mixed or conductive hearing loss or single-sided deafness implanted with an Osia implant. Participants will attend four study visits, where they will complete various hearing assessments using the Osia sound processors. conditions: Hearing Loss, Mixed Conductive-Sensorineural conditions: Hearing Loss, Conductive studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Within-subject primaryPurpose: TREATMENT masking: NONE count: 12 type: ESTIMATED name: Cochlear Osia 3 Sound Processor name: Cochlear™ Osia® 2 Sound Processor measure: Change (within subject) in speech reception threshold in noise with fixed noise level at 65 dB SPL measure: Change (within subject) in word recognition score in quiet measured at 65 dB SPL measure: Change (within subject) in aided thresholds in sound field measured at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0 and 8.0 kHz measure: Change (within subject) in the subjective rating of different aspects of sound when listening to sound clips measure: Percentage of participants who preferred Osia 3 over Osia 2 sound processor sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The HEARing CRC city: Melbourne state: Victoria zip: 3053 country: Australia name: Robert Cowan role: CONTACT phone: +61418780198 email: r.cowan@unimelb.edu.au lat: -37.814 lon: 144.96332 hasResults: False